Merck licenses SciBrunch's preclinical KRAS G12D inhibitor SPR2015 for $400M upfront

Merck signed an exclusive worldwide license with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D inhibitor that is still preclinical. SciBrunch receives a $400 million upfront payment, and the deal is worth up to $2.13 billion including milestones. The release says the transaction has closed, and Merck expects a $400 million pre-tax charge in the third quarter, about $0.13 per share.

• Upfront payment $400M; total potential value $2.13B
• Pre-tax charge of $400M in Q3 2026, about $0.13 per share
• Merck gets worldwide rights to develop, manufacture and commercialize SPR2015